Omar advises a range of clients on issues including supply chain, drug pricing, launch strategy, and oncology market analytics and planning.

He brings deep expertise working on strategy, operations, commercialization, and analytics across core client segments.

Omar previously led McKesson Specialty Health’s multisource products group. In this role, he held P&L responsibilities for specialty generics, biosimilars, and drugs launching into crowded spaces. Omar also managed the development and execution of their oncology and rheumatology biosimilar strategies. Additionally, he integrated advanced analytics into key functions of McKesson’s business, including pricing strategy, customer segmentation, product campaign design, and portfolio optimization. Prior to McKesson, Omar held roles at A.T. Kearney, Chicago Venture Partners, Omnicell, and HDC Corporation.

Omar has an MBA from Chicago Booth School of Business, an MS in mechanical engineering from Stanford University, and a BS in mechanical engineering from Columbia University.  

Authored Content

An Avalere analysis found that Oncology Care Model (OCM) lung cancer episode expenditures increased over 20% from performance periods 2 to 6 while the benchmark price increased about 10% during this period. During this same period, The Center for Medicare & Medicaid Innovation (CMMI) included 20 lung-cancer-specific changes to the OCM Novel Therapy Adjustment (NTA) list. This dynamic supports the inclusion of tumor-specific adjustments in the future Oncology Care First (OCF) model to further account for advancements in cancer management.

Manufacturers currently in the developmental phase for drug assets targeting rare or orphan diseases should assess the commercialization implications when bringing novel therapies to market and how they may differ from the standard pharmaceutical supply chain and economics.

Avalere experts examined the changing oncology landscape amid the COVID-19 pandemic.

Earlier today, the Trump Administration released long-anticipated drug pricing reforms, including rules related to a Most Favored Nation (MFN) approach for drugs administered by providers in Medicare and rebate reform for the Medicare Part D program. Both rules represent fundamental shifts in our current system and have significant implications for manufacturers, health plans, pharmacies, providers, and patients.

Liquid biopsies test blood samples for circulating tumor DNA (tumor derived cell-free DNA), circulating tumor cells, cell-free tumor DNA, proteins, metabolites, exosomes, messenger RNA, and microRNAs. The promise of liquid biopsies is a new modality that screens for cancer in ways that complement and, in some cases, improve existing tests, and allow testing for early detection, cancer diagnosis, and monitoring of minimum residual disease and recurrence, without the need for invasive biopsies.

Join Avalere experts for Part 1 of our Market Access Enablement Strategies webinar series to learn about how life sciences companies are pivoting with pre-/post-new product launch strategies, including differential investments to inform market access execution.

In its proposed changes to the Medicare Physician Fee Schedule (MPFS) for Calendar Year 2019 (CY2019), the Centers for Medicare & Medicaid Services (CMS) proposes a potentially sweeping change to the way it values physician office and outpatient visits, also known as Evaluation & Management (E/M) codes.